PHF6 and invasive breast carcinoma: PHF6 was identified as an adverse factor for OS in liver hepatocellular carcinoma (LIHC), pancreatic adenocarcinoma (PAAD), and breast invasive carcinoma (BRCA) (Figure 2A).